{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["17(1)"],"submitter":["Goswami SG"],"pubmed_abstract":["Background
Hereditary persistence of Fetal Hemoglobin (HPFH) is a benign condition known to mitigate symptoms in individuals with co-inherited β-hemoglobinopathies, such as β-thalassemia (BT) and sickle cell disease (SCD), through the reactivation of fetal hemoglobin (HbF). HPFH typically arises from deletions of varying sizes affecting the β-globin gene cluster or point mutations in the promoters of the γ-globin genes. While the therapeutic benefits of point mutations have been extensively studied, the potential of deletional forms of HPFH remains underexplored in preclinical settings.Method
In this study, we generated benign deletional HPFH3 genotype in SCD and BT patient-derived HSPCs using CRISPR/Cas9 and showed that therapeutically relevant levels of HbF reactivation r"],"journal":["Stem cell research & therapy"],"pagination":["46"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12836809"],"repository":["biostudies-literature"],"pubmed_title":["CRISPR editing of HPFH3 genotype induces γ-globin expression and reverses sickle cell disease and β-thalassemia phenotypes."],"pmcid":["PMC12836809"],"pubmed_authors":["Jain S","Mehta P","Ramalingam S","Goswami SG","Bhargava N","Iyer AR","Bajaj A","Saravanakumar V","Gunda P","Nakamura Y","Kurita R","Arvinden VR","Jha SK","Singh P","Singh S","Kumar A","Gupta P","Yadav P"],"additional_accession":[]},"is_claimable":false,"name":"CRISPR editing of HPFH3 genotype induces γ-globin expression and reverses sickle cell disease and β-thalassemia phenotypes.","description":"Background
Hereditary persistence of Fetal Hemoglobin (HPFH) is a benign condition known to mitigate symptoms in individuals with co-inherited β-hemoglobinopathies, such as β-thalassemia (BT) and sickle cell disease (SCD), through the reactivation of fetal hemoglobin (HbF). HPFH typically arises from deletions of varying sizes affecting the β-globin gene cluster or point mutations in the promoters of the γ-globin genes. While the therapeutic benefits of point mutations have been extensively studied, the potential of deletional forms of HPFH remains underexplored in preclinical settings.Method
In this study, we generated benign deletional HPFH3 genotype in SCD and BT patient-derived HSPCs using CRISPR/Cas9 and showed that therapeutically relevant levels of HbF reactivation r","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-15T03:17:24.029Z","creation":"2026-06-15T03:11:16.422Z"},"accession":"S-EPMC12836809","cross_references":{"pubmed":["41423621"],"doi":["10.1186/s13287-025-04582-1"]}}